Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial

Lancet

Volumn 353, Issue 9155, 1999, Pages 773-780

  Shaffer, Nathan ^a,d   Chuachoowong, Rutt ^a   Mock, Philip A ^a   Bhadrakom, Chaiporn ^b   Siriwasin, Wimol ^c   Young, Nancy L ^a,d   Chotpitayasunondh, Tawee ^c   Chearskul, Sanay ^b   Roongpisuthipong, Anuvat ^b   Chinayon, Pratharn ^c   Karon, John ^d   Mastro, Timothy D ^a,d   Simonds, R J ^d  

^a HIV/AIDS Collaboration   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Bangkok Children's Hospital   (Thailand)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; ARTIFICIAL MILK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABOR; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEWBORN; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THAILAND; THIRD TRIMESTER PREGNANCY; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TITRATION;

EID: 0033528520     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)10411-7     Document Type: Article

References (35)

1. World Health Organization. Global AIDS surveillance, part I. Wkly Epidemiol Rec 1997; 72: 357-60.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80.
3. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996; 335: 1621-29.
4. Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994; 43 (RR-11): 1-20.
5. Oxtoby MJ. Perinatally acquired human immunodeficiency virus infection. Pediatr Infect Dis J 1990; 9: 609-19.
6. Mofenson LM. Epidemiology and determinants of vertical HIV transmission. Semin Pediatr Infect Dis 1994; 5: 252-65.
7. Dunn DT, Newell ML. Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340: 585-88.
8. Ekpini ER, Wiktor SZ, Satten GA, et al. Late postnatal mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire. Lancet 1997; 349: 1054-59.
9. Leroy V, Newell ML, Dabis F, et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet 1998; 352: 597-600.
10. Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model: the HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol 1995; 142: 1330-37.
11. Kuhn L, Abrams EJ, Matheson PB, et al. Timing of maternal-infant HIV transmission: associations between intrapartum factors and early polymerase chain reaction results. AIDS 1997; 11: 429-35.
12. Mock PA, Shaffer N, Bhadrakom C, et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. AIDS 1999; 13: 406-14.
13. Siriwasin W, Shaffer N, Roongpisuthipong A, et al. HIV prevalence, risk factors and partner serodiscordance among pregnant women, Bangkok, Thailand. JAMA 1998; 280: 49-54.
14. Centers for Disease Control and Prevention. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission: Thailand, 1996-1998. MMWR Morb Mortal Wkly Rep 1998; 47: 151-54.
15. US National Institute of Allergy and Infectious Diseases, Division of AIDS Regulatory Operations Center. Serious adverse experiences reporting manual. Rockville, MD USA: National Institute of Allergy and Infectious Diseases, 1998.
16. Young N, Shaffer N, Chaowanachan T, et al. Modified Amplicor HIV-1 polymerase chain reaction assay in Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 391-92.
17. Shaffer N, Bhiraleus P, Chinayon P, et al. High viral load predicts perinatal HIV-1 subtype E transmission, Bangkok, Thailand. XI International Conference on AIDS; Vancouver, Canada: July 1996 (abstr).
18. Shaffer N, Roongpisuthipong A, Siriwasin W, et al. Maternal viral load and perinatal HIV-1 subtype E transmission, Bangkok, Thailand. J Infect Dis 1999; 179: 590-99.
19. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
20. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
21. Breslow NE, Day NE. Statistical methods in cancer research, vol 1: the analysis of case-control studies - IARC Scientific Publications No. 32. Lyon: International Agency for Research on Cancer, 1980.
22. Bryson YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992; 327: 1246-47.
23. Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11: 167-78.
24. Chearskul S, Chuachoowong R, Chotpitayasunondh T, et al. Concentration of zidovudine in umbilical cord blood after intermittent oral administration during labor, Thailand: a conference on global strategies for the prevention of HIV transmission from mothers to infants. Washington DC: September 1997 (abstr).
25. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban countries. JAMA 1996; 275: 1483-88.
26. Centers for Disease Control and Prevention. Update: perinatally acquired HIV/AIDS - United States, 1997. MMWR Morb Mortal Wkly Rep 1997; 46: 1086-92.
27. Centers for Disease Control and Prevention. Public health service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998; 47: 1-30.
28. Mayaux MJ, Teglas JP, Mandelbrot L, et al. Acceptability and impact of zidovudine for prevention of mother-to-child human innumodeficiency virus-1 transmission in France. J Pediatr 1997; 131: 857-62.
29. Simonds RJ, Steketee R, Nesheim S, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of human immunodeficiency virus. AIDS 1998; 12: 301-08.
30. Gorsky RD, Farnham PG, Straus WL, et al. Preventing perinatal transmission of HIV-costs and effectiveness of a recommended intervention. Public Health Rep 1996; 111: 335-41.
31. World Health Organization. Recommendations on the safe and effective use of short-course ZDV for prevention of mother-to-child transmission of HIV. Wkly Epidemiol Rec 1998; 73: 313-20.
32. Eastman NS, Shapiro DE Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS clinical trials group protocol 076. J Infect Dis 1998; 177: 557-64.
33. Read J. Mode of delivery and vertical transmission of HIV-1: a meta-analysis from fifteen prospective cohort studies (the International Perinatal HIV Group). Geneva: 12th World AIDS Conference, June 1998 (abstr 23275).
34. Mandelbrot L, Le Chanadec J, Berrebi A, et al. Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French perinatal cohort. JAMA 1998; 280: 55-60.
35. Moodley J, Moodley K, Pillay H, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1 infected pregnant women and their offspring. J Infect Dis 1998; 178: 1327-33.